Cardiometabolic risk factors and their treatment in patients with Type 2 diabetes

References

• International Diabetes Federation. Diabetes Atlas: Executive Summary. (2003).
   Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature414(6865), 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Norris SL, Zhang X, Avenell A et al. Long-term non-pharmacologic weight loss interventions for adults with Type 2 diabetes. Cochrane Database Syst. Rev.(2), CD004095 (2005).
   Google Scholar
• Daousi C CI, Gill G, MacFarlane IA, Wilding JPH, Pinkney JH. Obesity in Type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad. Med. J. (2005) (In Press).
   Google Scholar
• Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br. Med. J.316(7134), 823–828 (1998).
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. Br. Med. J.322(7288), 716–720 (2001).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet366(9497), 1640–1649 (2005).
   PubMed Web of Science ®Google Scholar
• Pouliot MC, Despres JP, Lemieux S et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol.73(7), 460–468 (1994).
   PubMed Web of Science ®Google Scholar
• Bigaard J, Frederiksen K, Tjonneland A et al. Waist and hip circumferences and all-cause mortality: usefulness of the waist-to-hip ratio? Int. J. Obes. Relat. Metab. Disord.28(6), 741–747 (2004).
   PubMed Web of Science ®Google Scholar
• Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol.288(5), H2031–2041 (2005).
   PubMed Web of Science ®Google Scholar
• Trayhurn P. The biology of obesity. Proc. Nutr. Soc.64(1), 31–38 (2005).
   PubMed Web of Science ®Google Scholar
• Wahrenberg H, Hertel K, Leijonhufvud BM et al. Use of waist circumference to predict insulin resistance: retrospective study. Br. Med. J.330(7504), 1363–1364 (2005).
   PubMed Web of Science ®Google Scholar
• Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab.89(6), 2595–2600 (2004).
   PubMed Web of Science ®Google Scholar
• Arner P. Insulin resistance in Type 2 diabetes – role of the adipokines. Curr. Mol. Med.5(3), 333–339 (2005).
   PubMed Web of Science ®Google Scholar
• Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J. Biol. Chem.272(2), 971–976 (1997).
   PubMed Web of Science ®Google Scholar
• He J, Usui I, Ishizuka K et al. Interleukin-1α inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol. Endocrinol.20(1), 114–124 (2006).
   PubMedGoogle Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab.89(6), 2548–2556 (2004).
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev.24(3), 278–301 (2003).
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature409(6818), 307–312 (2001).
   PubMed Web of Science ®Google Scholar
• Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J. Clin. Endocrinol. Metab.91(7), 2755–2760 (2006).
   PubMed Web of Science ®Google Scholar
• Heptulla R, Smitten A, Teague B et al. Temporal patterns of circulating leptin levels in lean and obese adolescents: relationships to insulin, growth hormone, and free fatty acids rhythmicity. J. Clin. Endocrinol. Metab.86(1), 90–96 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM. Metabolic complications of obesity. Endocrine13(2), 155–165 (2000).
   PubMedGoogle Scholar
• Okosun IS, Dever GE. Abdominal obesity and ethnic differences in diabetes awareness, treatment, and glycemic control. Obes. Res.10(12), 1241–1250 (2002).
   PubMedGoogle Scholar
• Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J.321(7258), 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• Carey VJ, Walters EE, Colditz GA et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study. Am. J. Epidemiol.145(7), 614–619 (1997).
   PubMed Web of Science ®Google Scholar
• Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of Type 2 diabetes among men. Am. J. Clin. Nutr.81(3), 555–563 (2005).
   PubMed Web of Science ®Google Scholar
• Despres JP, Moorjani S, Lupien PJ et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis10(4), 497–511 (1990).
   PubMedGoogle Scholar
• Lemieux I, Pascot A, Couillard C et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation102(2), 179–184 (2000).
   PubMed Web of Science ®Google Scholar
• Pascot A, Lemieux I, Prud’homme D et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J. Lipid Res.42(12), 2007–2014 (2001).
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis153(2), 263–272 (2000).
   PubMed Web of Science ®Google Scholar
• Robins S, Collins D, Rubins HB. Diabetes, hyperinsulinemia and recurrent coronary events in the VA-High Density Lipoprotein Intervention Trial (VA-HIT). Circulation102, (2000) (Abstract II-847).
   Google Scholar
• Joint-British-Societies. JBS 2: joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart91(Suppl. 5), V1–V52 (2005).
   PubMed Web of Science ®Google Scholar
• Busetto L, Sergi G, Enzi G et al. Short-term effects of weight loss on the cardiovascular risk factors in morbidly obese patients. Obes. Res.12(8), 1256–1263 (2004).
   PubMedGoogle Scholar
• Williamson DF, Pamuk E, Thun M et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am. J. Epidemiol.141(12), 1128–1141 (1995).
   PubMed Web of Science ®Google Scholar
• Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care20(4), 537–544 (1997).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med.344(18), 1343–1350 (2001).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346(6), 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Eriksson J, Lindstrom J, Valle T et al. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia42(7), 793–801 (1999).
   PubMed Web of Science ®Google Scholar
• Gillies CL, Abrams KR, Lambert PC et al. Pharmacological and lifestyle interventions to prevent or delay Type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Br. Med. J.334(7588), 299 (2007).
   PubMed Web of Science ®Google Scholar
• McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese Type 2 diabetic patients treated with metformin. Diabetes Care26(1), 125–131 (2003).
   PubMed Web of Science ®Google Scholar
• Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur. Heart J.7(Suppl. 7), L32–L38 (2005).
   Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care27(1), 155–161 (2004).
   PubMed Web of Science ®Google Scholar
• Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes. Res.8(1), 49–61 (2000).
   PubMedGoogle Scholar
• Sjostrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet352(9123), 167–172 (1998).
   PubMed Web of Science ®Google Scholar
• Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int. J. Obes. Relat. Metab. Disord.25(11), 1713–1721 (2001).
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet368(9548), 1660–1672 (2006).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet365(9468), 1389–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA295(7), 761–775 (2006).
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med.353(20), 2121–2134 (2005).
   PubMed Web of Science ®Google Scholar
• James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet356(9248), 2119–2125 (2000).
   PubMed Web of Science ®Google Scholar
• Behn A, Ur E. The obesity epidemic and its cardiovascular consequences. Curr. Opin. Cardiol.21(4), 353–360 (2006).
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med.348(5), 383–393 (2003).
   PubMed Web of Science ®Google Scholar
• Clegg AJ, Colquitt J, Sidhu MK et al. The clinical effectiveness and cost–effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol. Assess.6(12), 1–153 (2002).
   PubMedGoogle Scholar